WO2014060851A3 - Hepatitis c virus immunogenic compositions and methods of use thereof - Google Patents

Hepatitis c virus immunogenic compositions and methods of use thereof Download PDF

Info

Publication number
WO2014060851A3
WO2014060851A3 PCT/IB2013/003029 IB2013003029W WO2014060851A3 WO 2014060851 A3 WO2014060851 A3 WO 2014060851A3 IB 2013003029 W IB2013003029 W IB 2013003029W WO 2014060851 A3 WO2014060851 A3 WO 2014060851A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogenic compositions
methods
hepatitis
hcv
virus immunogenic
Prior art date
Application number
PCT/IB2013/003029
Other languages
French (fr)
Other versions
WO2014060851A2 (en
Inventor
John Law
Michael Logan
Darren HOCKMAN
D. Lorne Tyrrell
Michael Houghton
Original Assignee
The Governors Of The University Of Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Governors Of The University Of Alberta filed Critical The Governors Of The University Of Alberta
Publication of WO2014060851A2 publication Critical patent/WO2014060851A2/en
Publication of WO2014060851A3 publication Critical patent/WO2014060851A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure provides immunogenic compositions comprising HCV El and modified E2 polypeptides, wherein the modified E2 polypeptide comprises an amino acid substitution of asparagine in an E2N1 and/or E2N6 site. The immunogenic compositions are useful in earning out methods of inducing an immune response to HCV. The present disclosure further provides methods of stimulating an immune response to HCV in an individual.
PCT/IB2013/003029 2012-10-05 2013-10-04 Hepatitis c virus immunogenic compositions and methods of use thereof WO2014060851A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261710533P 2012-10-05 2012-10-05
US61/710,533 2012-10-05
US201261729135P 2012-11-21 2012-11-21
US61/729,135 2012-11-21

Publications (2)

Publication Number Publication Date
WO2014060851A2 WO2014060851A2 (en) 2014-04-24
WO2014060851A3 true WO2014060851A3 (en) 2014-09-12

Family

ID=50488838

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2013/003029 WO2014060851A2 (en) 2012-10-05 2013-10-04 Hepatitis c virus immunogenic compositions and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2014060851A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210145963A9 (en) * 2013-05-15 2021-05-20 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
EP3319997A4 (en) * 2015-07-07 2019-01-23 The Governors of the University of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
CN108290960B (en) 2015-10-08 2023-06-09 艾伯塔大学理事会 Hepatitis C virus E1/E2 heterodimer and method for producing the same
CN112601548A (en) * 2018-03-16 2021-04-02 艾伯塔大学理事会 Hepatitis C virus peptide compositions and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FALKOWSKA, E. ET AL., JOURNAL OF VIROLOGY., vol. 81, no. 15, August 2007 (2007-08-01), pages 8072 - 8079 *
HELLE, F. ET AL.: "Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious vinons.", JOURNAL OF VIROLOGY, vol. 84, no. 22, November 2010 (2010-11-01), pages 11905 - 11915 *
HELLE, F. ET AL.: "The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein.", JOURNAL OF VIROLOGY, vol. 81, no. 15, August 2007 (2007-08-01), pages 8101 - 8111 *

Also Published As

Publication number Publication date
WO2014060851A2 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
EP4349405A3 (en) Respiratory virus vaccines
WO2011103453A3 (en) Vaccines for use in the prophylaxis and treatment of influenza virus disease
MX2021001053A (en) Influenza virus vaccines and uses thereof.
IN2014KN03063A (en)
WO2013106834A3 (en) Immunogenic wt-1 peptides and methods of use thereof
WO2013040492A3 (en) Methods for treating hcv
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
UA113956C2 (en) PIRIMIDIN DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
JP2011136997A5 (en)
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
DK2707393T3 (en) FUSION PROTEINS AND COMBINATION VACCINES COVERING HAEMOPH-ILUS INFLUENZAE PROTEIN E AND PILIN A
WO2010036970A3 (en) Influenza vaccines, antigens, compositions, and methods
TR201905619T4 (en) Peptide carrier fusion proteins as allergy vaccines.
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
IN2015DN02546A (en)
BR112013030396A2 (en) polypeptide, polynucleotide, vector, host cell, immunogenic composition, vaccine, and use of an immunogenic composition or vaccine
WO2015052543A3 (en) Malaria vaccination
IN2012DN03209A (en)
PH12017500450A1 (en) Flavivirus virus like particle
WO2014060851A3 (en) Hepatitis c virus immunogenic compositions and methods of use thereof
WO2012054907A3 (en) Novel hemagglutinin 5 (h5) proteins for the treatment and prevention of influenza infections
NZ602380A (en) Peptides for vaccine against birch allergy
CL2012003219A1 (en) Recombinant parapoxvirus comprising a parapoxvirus and heterologous DNA derived from a rabies virus; preparation process of said parapoxvirus; immunogenic composition; use of the composition to induce immune response against rabies virus in an animal.
WO2014140166A3 (en) Vaccine
NZ704188A (en) Attenuated swine influenza vaccines and methods of making and use thereof

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13846770

Country of ref document: EP

Kind code of ref document: A2